DDR1 and neoplasm: Then, to profile DDR1 kinase signalling cascade in vivo, we harvested SW620‐DDR1 liver nodules from the nude mice treated or not with nilotinib (d7‐28) and described in Fig 3F. Western blot analysis revealed that nilotinib treatment did not affect MAPK and AKT activities, consistent with the RAS‐independent nature of DDR1 kinase signalling in these metastatic tumours (Fig EV2D).